Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the transaction, the chief operating officer now owns 329,977 shares of the company’s stock, valued at approximately $7,236,395.61. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Anish Patel also recently made the following trade(s):

• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00.

Enliven Therapeutics Trading Up 3.0 %

Enliven Therapeutics stock opened at $22.05 on Thursday. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03. The stock has a market cap of $1.08 billion, a P/E ratio of -11.61 and a beta of 1.03. The stock has a 50 day moving average of $22.67 and a 200-day moving average of $24.16.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ELVN shares. Robert W. Baird raised their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $38.25.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in shares of Enliven Therapeutics by 295.8% in the 3rd quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after purchasing an additional 42,012 shares during the last quarter. First Turn Management LLC increased its holdings in Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after buying an additional 121,849 shares during the last quarter. Geode Capital Management LLC raised its stake in Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after buying an additional 67,813 shares in the last quarter. Ally Bridge Group NY LLC bought a new position in Enliven Therapeutics during the 3rd quarter worth approximately $5,998,000. Finally, Patient Square Capital LP bought a new position in Enliven Therapeutics during the 3rd quarter worth approximately $2,313,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.